ValuEngine Lowers Vital Therapies (NASDAQ:VTL) to Strong Sell

ValuEngine cut shares of Vital Therapies (NASDAQ:VTL) from a sell rating to a strong sell rating in a research note issued to investors on Friday, November 17th.

A number of other brokerages also recently weighed in on VTL. BidaskClub raised Vital Therapies from a buy rating to a strong-buy rating in a research report on Thursday, October 5th. Zacks Investment Research downgraded Vital Therapies from a hold rating to a sell rating in a research report on Thursday, October 5th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus price target of $8.00.

Vital Therapies (NASDAQ:VTL) traded up $0.15 during trading hours on Friday, hitting $4.80. The company had a trading volume of 140,938 shares, compared to its average volume of 147,791. Vital Therapies has a twelve month low of $2.25 and a twelve month high of $6.50.

Vital Therapies (NASDAQ:VTL) last announced its quarterly earnings results on Wednesday, October 25th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.02. During the same period last year, the company posted ($0.32) EPS. research analysts expect that Vital Therapies will post -1.29 EPS for the current year.

In other Vital Therapies news, Director Muneer A. Satter bought 130,000 shares of the business’s stock in a transaction on Thursday, September 14th. The stock was purchased at an average cost of $4.01 per share, for a total transaction of $521,300.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jean Jacques Bienaime bought 10,000 shares of the business’s stock in a transaction on Wednesday, September 13th. The shares were acquired at an average price of $4.00 per share, with a total value of $40,000.00. Following the completion of the purchase, the director now directly owns 65,119 shares of the company’s stock, valued at $260,476. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 190,000 shares of company stock valued at $737,800. 32.60% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP bought a new stake in Vital Therapies during the third quarter worth $116,000. JPMorgan Chase & Co. increased its holdings in shares of Vital Therapies by 1,985.3% during the third quarter. JPMorgan Chase & Co. now owns 25,462 shares of the company’s stock worth $123,000 after buying an additional 24,241 shares in the last quarter. New York State Common Retirement Fund acquired a new position in shares of Vital Therapies during the third quarter worth $213,000. Dowling & Yahnke LLC acquired a new position in shares of Vital Therapies during the third quarter worth $252,000. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Vital Therapies by 1.8% during the first quarter. Goldman Sachs Group Inc. now owns 64,545 shares of the company’s stock worth $258,000 after buying an additional 1,157 shares in the last quarter. Hedge funds and other institutional investors own 24.35% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “ValuEngine Lowers Vital Therapies (NASDAQ:VTL) to Strong Sell” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/05/vital-therapies-inc-vtl-downgraded-by-valuengine.html.

Vital Therapies Company Profile

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply